Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: Role of 5-HT(1B/1D) receptors and α2-adrenoceptors

British Journal of Pharmacology

Volumn 126, Issue 3, 1999, Pages 585-594

  Villalón, Carlos M ^a,b   De Vries, Peter ^b   Rabelo, Gonzalo ^a   Centurión, David ^a   Sánchez López, Araceli ^a   Saxena, Pramod ^b  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

5 HT(1B 1D) receptors; 5 hydroxytryptamine (5 HT); Carotid artery; Dihydroergotamine; Dog; Ergotamine; GR127935; Methysergide; Prazosin; Yohimbine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ANTIMIGRAINE AGENT; DIHYDROERGOTAMINE; ERGOTAMINE; METHYSERGIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; PRAZOSIN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; YOHIMBINE;

ANIMAL EXPERIMENT; ARTERY CONSTRICTION; ARTICLE; CAROTID ARTERY FLOW; DOG; DOSE RESPONSE; EXTERNAL CAROTID ARTERY; FEMALE; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BLOOD FLOW VELOCITY; CAROTID ARTERIES; CLONIDINE; DIHYDROERGOTAMINE; DOGS; ERGOTAMINE; FEMALE; HEMODYNAMIC PROCESSES; MALE; METHYSERGIDE; OXADIAZOLES; PHENYLEPHRINE; PIPERAZINES; PRAZOSIN; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SUMATRIPTAN; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; YOHIMBINE;

EID: 0032982952     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702324     Document Type: Article

References (54)

1. 1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc. Natl. Acad. Sci. U.S.A., 90, 408-412.
2. 7) positively linked to adenylate cyclase. J. Biol. Chem., 268, 23422-23426.
3. 2B) in rat stomach fundus longitudinal muscle. Br. J. Pharmacol., 112, 323-331.
4. BOUCHELET, I., COHEN, Z., CASE, B., SEGUELA, P. & HAMEL, E. (1996). Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol. Pharmacol., 50, 219-223.
5. 1-like receptors. Br. J. Pharmacol., 104, 183-189.
6. 1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br. J. Pharmacol., 102, 323-330.
7. 1D receptor antagonist. Br. J. Pharmacol., 118, 85-92.
8. 1D (BRLI5572) receptor antagonists. Eur. J. Pharmacol., 362, 69-72.
9. 1B/1D and novel receptors. Br. J. Pharmacol., 123, 1561-1570.
10. GLUSA, E. & ROOS, A. (1996). Endothelial 5-HT receptors mediate relaxation of porcine pulmonary arteries in response to ergotamine and dihydroergotamine. Br. J. Pharmacol., 119, 330-334.
11. 1B receptors causes hypothermia in the guinea pig. Eur. J. Pharmacol., 331, 169-174.
12. 1D receptor subtypes. Trends Pharmacol. Sci., 17, 103-105.
13. HEYCK, H. (1969). Pathogenesis of migraine. Res. Clin. Stud. Headache, 2, 1-28.
14. HOFFMAN, B.B. & LEFKOWITZ, R.J. (1996). Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists. In Goodman & Gilman's The Pharmacological Basis of Therapeutics. eds. Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W. & Goodman Gilman, A., pp. 199-248: McGraw-Hill Book Co.
15. 1 recognition sites. J. Rec. Res., 8, 59-81.
16. HOYER, D., CLARKE, D.E., FOZARD, J.R., HARTIG, P.R., MARTIN, G.R., MYLECHARANE, E.J., SAXENA, P.R. & HUMPHREY, P.P. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev., 46, 157-203.
17. 2-mimetic activity in arteries and veins. In Vascular serotonin receptors (Ph.D. Thesis, University of Amsterdam), 83-94. Amsterdam: Rodopi.
18. KLEINMAN, L.I. & RADFORD, E.P. (1964). Ventilation standards for small mammals. J. Appl. Physiol., 19, 360-362.
19. LEYSEN, J.E. (1985). Serotonergic binding sites. In Serotonin and the cardiovascular system, eds. Vanhoutte, P.M., 43-62. New York: Raven Press.
20. LEYSEN, J.E. & GOMMEREN, W. (1984). In vitro binding profile of drugs used in migraine. In The pharmacological basis of migraine therapy, eds. Amery, W.K., Van Neuten, J.M. & Wauquier, A., 255-266. London: Pitman Publishing Ltd.
21. 3H]alniditan. Mol. Pharmacol., 50, 1567-1580.
22. MAASSENVANDENBRINK, A., REEKERS, M., BAX, W.A., BERRARI, M.D. & SAXENA, P.R. (1998). Coronary side-effect potential of current and prospective antimigraine drugs. Circulation, 98, 25-30.
23. MARTIN, G.R. (1994). Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacol. Ther., 62, 283-324.
24. 1D receptor agonist effects of dihydroergotamine. Studies using a model to differentiate slow drug-receptor dissociation from diffusion. In Experimental headache models. eds. Olesen, J. & Moskowitz, M.A., 163-167. Philadelphia: Lippincott-Raven Publishers.
25. MASSINGHAM, R. & HAYDEN, M.L. (1975). A comparison of the effects of prazosin and hydrallazine on blood pressure, heart rate and plasma renin activity in conscious renal hypertensive dogs. Eur. J. Pharmacol., 30, 121-124.
26. MÜLLER-SCHWEINITZER, E. (1984). Alpha-adrenoceptors, 5-hydroxytryptamine receptors and the action of dihydroergotamine in human venous preparations obtained during saphenectomy procedures for varicose veins. Naunyn-Schmiedeberg's Arch. Pharmacol., 327, 299-303.
27. MÜLLER-SCHWEINITZER, E. & WEIDMANN, H. (1978). Basic pharmacological properties. In Ergot alkaloids and related compounds. eds. Berde, B. & Schild, H.O., pp. 87-232. Berlin, Heidelberg, New York: Springer Verlag.
28. MYLECHARANE, E.J., SPIRA, P.J., MISBACH, J., DUCKWORTH, J.W. & LANCE, J.W. (1978). Effects of methysergide, pizotifen and ergotamine in the monkey cranial circulation. Eur. J. Pharmacol., 48, 1-9.
29. 1B/D receptor antagonist GR127935. CNS Drug Rev., 2, 415-428.
30. 1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci., 61, 2117-2126.
31. 1D receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 356, 312-320.
32. RAMAGE, A.G. & TOMLINSON, A. (1985). The effect of yohimbine, WY 26392 and idazoxan on sympathetic nerve activity. Eur. J. Pharmacol., 109, 153-160.
33. SAXENA, P.R. (1974a). Selective carotid vasoconstriction by ergotamine as a relevant mechanism in its antimigraine action. Arch. Neurobiol., 37, S301-S315.
34. SAXENA, P.R. (1974b). Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effect. Eur. J. Pharmacol., 27, 99-105.
35. SAXENA, P.R. (1995). Cranial arteriovenous shunting, an in vivo animal model for migraine. In Experimental headache models. eds. Olesen, J. & Moskowitz, M.A., pp. 189-198. Philadelphia: Lippincott-Raven Publishers.
36. SAXENA, P.R. & DE VLAAM-SCHLUTER, G.M. (1974). Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine-studies in an experimental model for migraine. Headache, 13, 142-163.
37. 1-like receptors: a time to bid good-bye. Trends Pharmacol. Sci., 19, 311-316.
38. 1D receptor agonists in development for the acute treatment of migraine. In Headache treatment: trial methodology and new drugs. eds. Olesen, J. & Tfelt-Hansen, P., pp. 229-241. New York: Lippincott-Raven publishers.
39. SAXENA, P.R., KOEDAM, N.A., HEILIGERS, J. & HOF, R.P. (1983). Ergotamine-induced constriction of cranial arteriovenous anastomoses in dogs pretreated with phentolamine and pizotifen. Cephalalgia, 3, 71-81.
40. 1 receptors. Arch. Int. Pharmacodyn. Ther., 277, 235-252.
41. SAXENA, P.R. & VERDOUW, P.D. (1984). Effects of methysergide and 5-hydroxytryptamine on carotid blood flow distribution in pigs: further evidence for the presence of atypical 5-HT receptors. Br. J. Pharmarol., 82, 817-826.
42. SHEPPERSON, N.B., DUVAL, N., MASSINGHAM, R. & LANGER, S.Z. (1981). Pre- and postsynaptic alpha adrenoceptor selectivity studies with yohimbine and its two diastereoisomers rauwolscine and corynanthine in the anesthetized dog. J. Pharmacol. Exp. Ther., 219, 540-546.
43. 1D receptor antagonist. Behav. Brain Res., 73, 157-161.
44. SPIERINGS, E.L. & SAXENA, P.R. (1980). Antimigraine drugs and cranial arteriovenous shunting in the cat. Neurology, 30, 696-701.
45. STEEL, R.G.D. & TORRIE, J.H. (1980). Principles and procedures of statistics. A biomedical approach (2nd edition), Tokyo: McGraw-Hill Kogakusha Ltd.
46. 1-adrenoceptors in the reduction of external carotid blood flow induced by buspirone and ipsapirone in the dog. Life Sci., 58, 63-73.
47. VILLALÓN, C.M., BOM, A.H., DEN BOER, M.O., HEILIGERS, J.P. & SAXENA, P.R. (1992). Effects of S9977 and dihydroergotamine in an animal experimental model for migraine. PharmacoL Res., 25, 125-137.
48. 7 receptor. Br. J. Pharmacol., 120, 1319-1327.
49. 7 receptors mediating tachycardia in the cat. Br. J. Pharmacol., 121, 1187-1195.
50. VILLALÓN, C.M., RABELO, G., SÁNCHEZ, A., CENTURIÓN, D., DE VRIES, P. & SAXENA, P.R. (1998). Pharmacological profile of the receptors involved in the external carotid vasoconstrictor response to ergotamine, dihydroergotamine and methysergide in the dog. Naunyn-Schmiedeberg's Arch. Pharmacol., 358, R229.
51. VILLALÓN, C.M., RAMIREZ-SAN, JUAN, E., CASTILLO, C., CASTILLO, E., LOPEZ-MUNOZ, F.J. & TERRÓN, J.A. (1995). Pharmacological profile of the receptors that mediate external carotid vasoconstriction by 5-HT in vagosympathectomized dogs. Br. J. Pharmacol., 116, 2778-2784.
52. 1D receptor subtype. Naunyn-Schmiedeberg's Arch. Pharmacol., 354, 550-556.
53. VILLALÓN, C.M. & TERRÓN, J.A. (1994). Characterization of the mechanisms involved in the effects of catecholamines on the canine external carotid blood flow. Can. J. Physiol. Pharmacol., 72, 165.
54. 1-like receptors in the increase in external carotid blood flow induced by 5-hydroxytryptamine in the dog. Eur. J. Pharmacol., 240, 9-20.